Home › Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
 

Keywords :   


Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program

2014-07-30 10:52:33| drugdiscoveryonline Home Page

Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration (FDA) has designated the HumaGraft development program for vascular access in hemodialysis patients as a Fast Track Development Program

Tags: program access fast track

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.07Tropical Storm Beryl Graphics
05.07Atlantic Tropical Weather Outlook
05.07Tropical Storm Beryl Public Advisory Number 28A
05.07Summary for Tropical Storm Beryl (AT2/AL022024)
05.07Still no sign of herd rebuilding
05.07Eastern North Pacific Tropical Weather Outlook
05.07Tubi and Pluto lead U.S. surge in free streaming
05.07Tubi free streaming service launches in the UK
More »